Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers
Authors:
- Guanjie LiGLGuanjie Li
- Hiroyuki SuzukiHSHiroyuki Suzuki
- Tomokazu OhishiTOTomokazu Ohishi
- Hiroyuki SatofukaHSHiroyuki Satofuka
- Kenichiro IshikawaKIKenichiro Ishikawa
- Kai ShimizuKSKai Shimizu
- Airi NomuraANAiri Nomura
- Haruto ArakiHAHaruto Araki
- Naoki KojoNKNaoki Kojo
- Kaito SuzukiKSKaito Suzuki
- Saori HandaSHSaori Handa
- Takuro NakamuraTNTakuro Nakamura
Open Access
- 2 April 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3221
Abstract
Erythropoietin-producing hepatocellular receptor A2 (EphA2) has emerged as a key mediator that promotes tumor malignant progression. EphA2 overexpression and its non-canonical signaling lead to oncogenic transformation, metabolic reprogramming, resistance to treatments, and metastasis. Therefore, strategies targeting EphA2 have been evaluated in clinical trials. However, the clinical effects were not sufficient. An anti-EphA2 monoclonal antibody (mAb), Ea2Mab-7 (mouse IgG1, κ), demonstrated high affinity and specificity among Eph receptors. In this study, we produced recombinant class-switched Ea2Mab-7 variants, including Ea2Mab-7-mG2a (mouse IgG2a) and Ea2Mab-7-hG1 (human IgG1). Both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 recognized human triple-negative breast cancer MDA-MB-231, pancreatic cancer MIA PaCa-2, and colorectal cancer HCT-15 in flow cytometry. Furthermore, both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 exerted significant antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against these tumors. In mouse xenograft models of breast, pancreatic, and colorectal cancers, both mAbs demonstrated antitumor activity. These results indicate the potential of Ea2Mab-7 variants for the treatment of EphA2-positive cancers.Keywords
All Related Versions
Funding Information
- Japan Agency for Medical Research and Development (JP25am0521010)
- Japan Agency for Medical Research and Development (JP25ama121008)
- Japan Agency for Medical Research and Development (JP25ama221153)
- Japan Agency for Medical Research and Development (JP25ama221339)
- Japan Agency for Medical Research and Development (JP25bm1123027)
- Japan Society for the Promotion of Science (25K18843)
- Japan Society for the Promotion of Science (24K11652)
- Japan Society for the Promotion of Science (24K18268)
- Japan Society for the Promotion of Science (25K10553)
This publication has 56 references indexed in Scilit:
- Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applicationsBiochemistry and Biophysics Reports, 2025
- Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)Current Ophthalmology Reports, 2024
- A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancersInvestigational New Drugs, 2022
- Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLCCell Reports, 2020
- Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breastBreast Cancer Research and Treatment, 2019
- EphA2 Drives the Segregation of Ras-Transformed Epithelial Cells from Normal NeighborsCurrent Biology, 2016
- Epstein–Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant TransformationEBioMedicine, 2016
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsInvestigational New Drugs, 2012
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with AktCancer Cell, 2009
- Eph-Ephrin Bidirectional Signaling in Physiology and DiseaseCell, 2008